Treatment of Pineal Region Rosette-Forming Glioneuronal Tumors (RGNT)

Background: Rosette-forming glioneuronal tumor (RGNT) is an extremely rare entity described for the first time in the WHO classification of tumors of the central nervous system in 2007. Predominantly, single case reports of RGNT in the pineal region have been published, and specific therapy concepts...

Full description

Bibliographic Details
Main Authors: Anna Michel, Thiemo Florin Dinger, Ramazan Jabbarli, Philipp Dammann, Anne-Kathrin Uerschels, Marvin Darkwah Oppong, Neriman Özkan, Andreas Junker, Ulrich Sure, Karsten Henning Wrede
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/19/4634
Description
Summary:Background: Rosette-forming glioneuronal tumor (RGNT) is an extremely rare entity described for the first time in the WHO classification of tumors of the central nervous system in 2007. Predominantly, single case reports of RGNT in the pineal region have been published, and specific therapy concepts are pending. Methods: The study group comprised all patients with the RGNT (CNS WHO grade 1) in the pineal region that underwent microsurgical tumor removal in our center (August 2018–June 2021). Surgical strategy, histological findings, and clinical outcome are presented, and the results are evaluated and compared to published case reports. Results: Four male patients aged under 50 years (range between 20 and 48 years) and one female patient, 51 years old, were included in this study. Chronic headaches and generalized epileptic seizures were the main symptoms. Supra-cerebellar infratentorial gross total tumor resection (GTR) was performed in two cases, two patients underwent subtotal tumor resection, and an endoscopic biopsy was performed in case five. Conclusion: In cases where surgical resection seems feasible with a reasonable surgical risk, we advocate GTR. Regular and long-term MRI follow-up is essential to detect a slow tumor progression. The role of additional chemotherapy or radiotherapy remains unclear.
ISSN:2072-6694